Yan Sheng, Rodriguez-Barbosa Jose-Ignacio, Pabst Oliver, Beckmann Jan H, Brinkmann Volker, Förster Reinhold, Hoffmann Matthias W
Department of Surgery, The 1st Affiliated Hospital of Zhejiang University, Zhejiang, China.
Transplantation. 2005 Jun 27;79(12):1703-10. doi: 10.1097/01.tp.0000164501.65352.39.
The clinical application of small bowel transplantation (SBTx) is hampered by its pronounced immunogenicity. We aimed to test the hypothesis that prolonged sequestration of lymphocytes in secondary lymphoid organs may enhance the alloprotective effect of costimulation blockade.
For this purpose, recipients of intestinal allografts were treated with MR1, FTY720, combined FTY720 plus MR1, or were left untreated. Grafts were examined 6 and 14 days after transplantation by applying a histologic rejection score, multiparameter-immunofluorescent staining, and flow cytometry.
FTY720 or MR1 monotherapy did not prevent the rejection of mouse intestinal allografts, whereas combined therapy with FTY720 plus MR1 profoundly inhibited rejection at day 6 and day 14 after transplantation. In FTY720-treated mice infiltration of host lymphocytes in graft mesenteric lymph nodes, Peyer's patches, intraepithelial lymphocytes, and lamina propria lymphocytes (LPLs) was reduced on day 6. Anti-CD40L antibody improved the rejection score at day 14 but had no effect at day 6. Importantly, host CD8 T-cell infiltration in graft LPLs was significantly reduced compared with all other groups.
FTY720 plus MR1 effectively inhibited intestinal allograft rejection in mice, possibly by enhancing the alloprotective effects of costimulation blockade by prolonged sequestration of lymphocytes in secondary lymphoid organs.
小肠移植(SBTx)的临床应用因其明显的免疫原性而受到阻碍。我们旨在验证以下假设:淋巴细胞在二级淋巴器官中的长时间隔离可能增强共刺激阻断的同种异体保护作用。
为此,对肠道同种异体移植受体分别用MR1、FTY720、FTY720与MR1联合治疗,或不进行治疗。在移植后6天和14天,通过应用组织学排斥评分、多参数免疫荧光染色和流式细胞术对移植物进行检查。
FTY720或MR1单一疗法不能预防小鼠肠道同种异体移植的排斥反应,但FTY720与MR1联合疗法在移植后第6天和第14天能显著抑制排斥反应。在接受FTY720治疗的小鼠中,移植后第6天,移植物肠系膜淋巴结、派尔集合淋巴结、上皮内淋巴细胞和固有层淋巴细胞(LPLs)中的宿主淋巴细胞浸润减少。抗CD40L抗体在第14天改善了排斥评分,但在第6天没有效果。重要的是,与所有其他组相比,移植LPLs中宿主CD8 T细胞浸润显著减少。
FTY720加MR1可有效抑制小鼠肠道同种异体移植排斥反应,可能是通过在二级淋巴器官中长时间隔离淋巴细胞来增强共刺激阻断的同种异体保护作用。